恶性淋巴瘤患者血清中IL-2、sIL-2R、IL-6、IL-8和TNFα的测定

目的：探讨血清中细胞因子变化在恶性淋巴瘤（ＭＬ）中的意义。方法：采用放射免疫分析法及酶联免疫吸附法测定了４９例ＭＬ患者血清中白细胞介素２（ＩＬ－２）等５种细胞因子浓度。结果：除肿瘤坏死因子α（ＴＮＦα）外，大部分初治、复发患者中治疗前ＩＬ－２，可溶性白细胞介素２受体（ｓＩＬ－２Ｒ），ＩＬ－６，ＩＬ－８升高；治疗有反应的下降，完全缓解时与对照组无差异；治疗无反应的仍保持高水平。ＩＬ－２及ｓＩＬ－２Ｒ升高与患者的临床分期有关，Ⅲ、Ⅳ期患者较Ⅰ、Ⅱ期明显增高；ｓＩＬ－２Ｒ与肿瘤负荷有关；ＩＬ－６与患者有无Ｂ组症状相关，Ｂ组患者明显高于Ａ组，而与分期无关；ＩＬ－８升高与临床分期及Ｂ组症状有关，与其他临床血液学指标无关。结论：细胞因子的变化可以作为观察ＭＬ病情及监测治疗反应的一种手段。

Measurement of five cytokines in the serum of malignant lymphoma patients

OBJECTIVE: To study the clinical significance of serum cytokine levels in patients with malignant lymphoma(ML). METHODS: Serum levels of five cytokines and receptor were measured in 49 patients with ML by RIA and ELISA. RESULTS: Except TNF alpha, significantly higher pretreatment levels of interleukin-2(IL-2), soluble interleukin-2 receptor(sIL-2R), interleukin-6(IL-6) and interleukin-8(IL-8) were observed in most of ML patients at diagnosis or relapse as compared with controls(P < 0.05). Cytokine levels declined in responding patients after therapy and there were no differences between CR cases and controls, the cytokine levels remained elevated in non-responding patients. The levels of IL-2 and sIL-2R correlated with the clinical stage, which were significantly higher in patients in stage III, IV. The increase of sIL-2R correlated with the tumor burden. The level of IL-6 was higher in patients presenting B symptoms and had no correlation with the clinical stage. The elevated IL-8 level correlated with the clinical stage and presenting B symptoms of ML patients and had no correlation with other clinical-hematological parameters. CONCLUSION: The changes of cytokines may be served as a means to observe the condition of ML patients and supervise their response to treatment.